Phase 3 Trial of SPECT/CT Imaging for Lung Cancer

Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.
Researchers are attempting to determine whether SPECT/CT imaging is non-inferior to PET/CT imaging for lung cancer.

Title: A Multicenter Phase 3 Study Comparing the Diagnostic Accuracy of 99mTc EC DG SPECT/CT Versus 18F FDG PET/CT for Diagnosing and Staging Patients Who Have Clinical and Radiological (CT) Evidence Consistent With a Diagnosis of Lung Cancer1

Responsible Party: Cell>Point LLC

Description: For this non-randomized, open label, phase 3 study (ClinicalTrials.gov Identifier: NCT01394679), researchers are attempting to determine whether lung cancer diagnosis and staging using SPECT/CT 99mTC [technetium]-EC-DG [ethylenedicysteine-deoxyglucose] scanning is non-inferior to PET/CT 18F-FDG scanning.

Patients will undergo PET/CT imaging or SPECT/CT imaging. The primary outcomes are a comparison of the imaging techniques and non-inferiority of SPECT/CT; the secondary outcome is safety.

For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT01394679.

Status: This study is open and recruiting patients as of April 14, 2017.

This study is sponsored by Cell>Point LLC.

Reference

  1. Clinicaltrials.gov. A phase 3 study of 99mTC-EC-DG SPECT/CT versus PET/CT in lung cancer. NCT01394679. https://clinicaltrials.gov/ct2/show/NCT01394679. Accessed April 14, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters